• 中文核心期刊要目总览
  • 中国科技核心期刊
  • 中国科学引文数据库(CSCD)
  • 中国科技论文与引文数据库(CSTPCD)
  • 中国学术期刊文摘数据库(CSAD)
  • 中国学术期刊(网络版)(CNKI)
  • 中文科技期刊数据库
  • 万方数据知识服务平台
  • 中国超星期刊域出版平台
  • 国家科技学术期刊开放平台
  • 荷兰文摘与引文数据库(SCOPUS)
  • 日本科学技术振兴机构数据库(JST)
赵锋, 兰新强, 杜燕, 陈佩仪, 赵娇, 赵芳, 李文辉, 张云. 2018: 眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌. 动物学研究, 39(2): 87-96. DOI: 10.24272/j.issn.2095-8137.2018.025
引用本文: 赵锋, 兰新强, 杜燕, 陈佩仪, 赵娇, 赵芳, 李文辉, 张云. 2018: 眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌. 动物学研究, 39(2): 87-96. DOI: 10.24272/j.issn.2095-8137.2018.025
Feng Zhao, Xin-Qiang Lan, Yan Du, Pei-Yi Chen, Jiao Zhao, Fang Zhao, Wen-Hui Lee, Yun Zhang. 2018: King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zoological Research, 39(2): 87-96. DOI: 10.24272/j.issn.2095-8137.2018.025
Citation: Feng Zhao, Xin-Qiang Lan, Yan Du, Pei-Yi Chen, Jiao Zhao, Fang Zhao, Wen-Hui Lee, Yun Zhang. 2018: King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates. Zoological Research, 39(2): 87-96. DOI: 10.24272/j.issn.2095-8137.2018.025

眼镜王蛇多肽OH-CATH30可作为潜在候选药物分子杀死临床耐药菌

King cobra peptide OH-CATH30 as a potential candidate drug through clinic drug-resistant isolates

  • 摘要: 阳离子抗菌肽(antimicrobial peptides ,AMPs)被认为是一类重要的临床治疗药物的候选分子,它对细菌、真菌和部分病毒都具有有效的杀菌活性。基于我们此前的研究结果,眼镜王蛇cathelicidin(OH-CATH)是由34个氨基酸组成的多肽,具有很强的抑菌活性和较低的溶血活性。我们的研究目的是为了评价D型和L型 OH-CATH30和常用抗生素的临床病原菌抗菌活性。研究中共收集到584株临床病原菌(时间在2013–2016),根据国际CLSI标准用微量肉汤稀释法,来评价抗菌肽和常用抗生素的杀菌效果。这些临床病原菌中,85%对D型和L型OH-CATH30敏感。与常用抗生素相比,D型和L型OH-CATH30对革兰氏阳性菌具有较强的抑菌活性,并且对几乎所有的革兰氏阴性菌都具有很好的杀菌效果。尤其是对不动杆菌属,包括多重耐药鲍曼不动杆菌和甲氧西林耐药金黄色葡萄球菌,具有非常高的杀菌活性。总体而言,D型和L型OH-CATH30的抑菌活性要强于9种常用抗生素。因此,OH-CATH30是一种非常有前景的药物候选分子,可以用来治疗各种常规抗生素耐药菌引起的感染。

     

    Abstract: Cationic antimicrobial peptides (AMPs) are considered as important candidate therapeutic agents, which exert potent microbicidal properties against bacteria, fungi and some viruses. Based on our previous findings king cobra cathelicidin (OH-CATH) is a 34-amino acid peptide that exerts strong antibacterial and weak hemolytic activity. The aim of this research is to evaluate the efficacy of both OH-CATH30 and its analog D-OH-CATH30 against clinical isolates comparing with routinely utilized antibiotics in vitro. In this study, 584 clinical isolates were tested (spanning 2013–2016) and the efficacy of the candidate peptides and antibiotics were determined by a broth microdilution method according to the CLSI guidelines. Among the 584 clinical isolates, 85% were susceptible to OH-CATH30 and its analogs. Both L- and D-OH-CATH30 showed higher efficacy against (toward) Gram-positive bacteria and stronger antibacterial activity against nearly all Gram-negative bacteria tested compare with antibiotics. The highest bactericidal activity was detected against Acinetobacter spp., including multi-drug-resistant Acinetobacter baumannii (MRAB) and methicillin-resistant Staphylococcus aureus (MRSA). The overall efficacy of OH-CATH30 and its analogs was higher than that of the 9 routinely used antibiotics. OH-CATH30 is a promising candidate drug for the treatment of a wide variety of bacterial infections which are resistant to many routinely used antimicrobial agents.

     

/

返回文章
返回